http://clinicaltrialsfeeds.org/clinical-trials/show/NCT00563173

exclusion list in trials include: No cirrohsis, no HIV co-infection

Google 'ChronVac-C'  there were 656 hits listed, I believe that the english
version of what h00hbt gave us is here:

http://tripep.se/english/research_and_development/chronvac_c/

-cactus jammies-

My  2 cents, hey! IKEA changed the world of interior design so maybe
we beat this to?

just got the news and translated it with systran,................

/H

The first patient with chronic hepatit C infection has started its
treatment with Tripeps ChronVac-C® - vaccin.

This is the first time in the world someone vaccineras with one DNA-
vaccin against one infektionssjukdom through s.k in-vivo-
elektroporering.

The study covers totally twelve patients and three dose groups. Each
patient comes that few four ChronVac-C®-vaccinationer obvious with a
month's intervals. After last vaccinationen is followed the patients
additional during six months

Today's treatments of hepatit C has meagre effect, is expensive and
afflicted with significant problem and secondary effects. ChronVac-C®
is a treating vaccin against chronic hepatit C infection that, about
the now the initiated study shows good results, with considerable
fewer btreatments, fewer secondary effects and to substantially lower
costs should have good conditions to become first choice, says Tripeps
CEO Jan Nilsson.

The study is carried out on Infektionskliniken and Gastrocentrum, bode
at Karolinska Universitetssjukhuset in Huddinge, respective Solna in
Sweden. The study's central aim is to show that the treatment is safe,
but also to evaluate about the treatment can to activate the body's
immunsvar and impact on virusproduktionen in the liver.

ChronVac-C® is what man calls a treating vaccin, i.e. one vaccin that
is given to persons that already are hostile with HCV, in aim to
improve theirs immunsvar against the infection. ChronVac-C® is
moreover what man calls a genetic vaccin. That one vaccin is genetic
mean that one does not fulfil vaccinsprutan with vaccinet without with
the genetic code, dna, for vaccinet. When vaccinet been spurted in in
the muscle will dna be taken up of muscle cells that since can convert
dna to protein and to produce vaccinet alone so that the body's
immunförsvar is activated.

A big problem with this so-called DNA-vaccination, if one only uses a
common needle, is that vaccin-DNA usually stays outside the muscle
cells and is broken down. DNA-vaccin has however many advantages; they
are easy and cheap to produce, they can be stored during long time,
and same produktionsanläggning can produce a big number different
vaccin. In order to can to use these advantages must one the the loose
primary problem, i.e. that muscle cells do not take up DNA-vaccin.

One HCV-infektion in the liver does not activate immunsvaret
particularly effective, what can contribute to explaining why so
majority becomes chronic wearers. In other word can the last of big
value to activate one immunförsvar against some non changeable part of
HCV on other place in the body than in the liver. A good place is in
the body's muscles there vaccinationer usually happens.

Tripep has getupto a solution these problems through a cooperation
with the American company Inovio that is world-leading on so-called in-
vivo-elektroporering. This technology, that is carried out with
Inovios Medpulser® dna Delivery systems (DDS), mean that one sets
cells for short electrical pulser what causes lightly temporary holes
(porer) in the cell diaphragm, i.e. the cell's shells. When these
holes arise can dna effective to take itself in in the cell. After a
short while, the holes are sealed again.

Inovio has now developed the technology so that it can be used in
people. The treating doctor gives firstly one injektion of ChronVac-C®
in a muscle. Immediate then takes the doctor Medpulser® DDS and for in
its four electrode styluses in same area there vaccin-DNA was
injected. With Medpulser® DDS on-the-spot is given some short el-
pulser and then is the treatment clear. A complete behandlingsomgång
will cover four alike treatments with a month's intervals. The hope is
that this comes evil to that the body activates one immunsvar that
helps to healing out the infection.

The development of ChronVac-C® has been taking place since 1999. The
company has can take forward models that show what vaccinet can do.
ChronVac-C® can activate B-celler and T-celler. T-celler is they as
man today considers to last of biggest importance in order to heal out
a chronic infection. Mouse studies have shown that one ChronVac-C®-
vaccination activates T-celler that makeacommitmentto in the liver and
hits out liver cells that produce HCV-protein, a basic requirement in
order to a treating vaccin will function. The combination of ChronVac-
C® and Medpulser® DDS was noticed in connection with 2nd Hepatitis C
conference in Dublin June 23, 2006, there professor Matti Sällberg
presented good results from mouse studies. This was followed during
the year of more good results. The company could show that the
combination gave origins to T-cellssvar that can makeacommitmentto in
the liver and to hit out HCV protein producing liver cells. This is
actually one proof-of-concept for the combination of

ChronVac-C® and Medpulser® DDS and precise it that one wants to
achieve with a treating vaccination.

2006, one breakthrough sows for ChronVac-C®
2006 has so far meant several breakthroughs for ChronVac-C® and
several important objectives within the project has been achieved. In
January, the company could announce that one a been included
cooperation agreement with it San Diego-baserade the company Inovio
for a common clinical development of Chron-Vac-C®. The agreement gives
Inovio a may verge electricity in ChronVac-C® and in return gets the
company access to Inovios technology for DNA-vaccination on people.
During February was delivered GMP-framställt ChronVac-C® from Vecura
Ltd and two of Inovios Medpulser® DDS-utrustningar for in-vivo-
elektroporering to the company. This meant that it toxikologiska the
evaluation of ChronVac-C® immediate could be started. In March 2006
received the company the so far the most important patent for ChronVac-
C®. This patent protects it strongly modified and improved hepatit C-
virusgenen that is in ChronVac-C®. With this has Tripep itself
läkemedelskandidat ChronVac-C® safe in smallest 17 years. Three
toxikologiska studies has now been implemented, one for cinema
distribution and farmakokinetik, an urgent toxikologisk study and one
in order to see effects of repeated administration. These studies were
completed during the third and fourth quarter 2006. Analog was put
together all necessary documentation for application to ethics
committee respective Medical Products Agency in order to a phase I-
studie on fresh voluntary will can to be started as soon as possible.
In December, the company could submit all documents to Medical
Products Agency.